Compare Hyatt Hotels Corporation (H) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs 10X Genomics Inc — how do they compare? Hyatt Hotels Corporation trades at $159.66 (market cap $15.02B), while 10X Genomics Inc trades at $82.03 (market cap $10.07B). The key difference: Hyatt Hotels Corporation is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and 10X Genomics Inc for 92 Days on average.
| H | TXG | |
|---|---|---|
Market Cap | $15.02B | $10.07B |
Volume | 842,340 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $97.74 |
52-Week Low | $135.42 | $11.48 |
Typical Hold Time | 148 Days | 92 Days |
Enterprise Value | $18.93B | $9.59B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $160.27, up 1.99% with recent earnings beats but faces bearish technical signals. The stock shows mixed fundamentals with a high P/E of 196.83 and modest net income margin of 1.1%, though revenue growth to $7.10B in 2025 and strategic collaborations with Delta Air Lines highlight expansion efforts. Analyst consensus is moderately bullish with a $197.77 price target, but negative cash flow trends and elevated debt levels present challenges.
Outlook remains cautious due to valuation concerns and operational headwinds, though long-term growth initiatives offer potential upside. Key risks include profit margin volatility, high leverage, and competitive pressure. Investors should weigh analyst optimism against fundamental weaknesses before positioning.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
